HIGHLIGHTS
- who: Ran Ran and colleagues from the Institut du de Montpellier (ICM), France University, China have published the research work: Treatment strategies for hormone receptor-positive, human epidermal growth factor receptor 2-positive (HR+/HER2+) metastatic breast cancer: A review, in the Journal: (JOURNAL)
- how: The results showed that the PFS of patients receiving sequential endocrine therapy after trastuzumab plus chemotherapy was longer compared with those receiving trastuzumab plus chemotherapy or trastuzumab plus endocrine or single endocrine therapy (21.3 vs 9.5 vs 13.8 vs 4.8 months). The results showed that endocrine . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.